Exagen Inc. (XGN) reported Q3 EPS of ($0.47), $0.29 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $9.13 million.
GUIDANCE:
Exagen Inc. sees FY2022 revenue of $40-43 million, versus the consensus of $38 million.